Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Ifrah

Showing results (161-170 of 169) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 169 results.
Leukemia|September 18, 2020
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO studyLaetitia Largeaud, Pascale Cornillet-Lefebvre, Jean-François Hamel, et al.
Nature Communications|January 24, 2015
Site- and allele-specific polycomb dysregulation in T-cell leukaemiaJean-Marc Navarro, Aurore Touzart, Lydie C Pradel, et al.
Blood|May 13, 2026
Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST StudyNicolas Boissel, Françoise Huguet, Thibaut Tl Leguay, et al.
Blood|April 29, 2016
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALLPhilippe Rousselot, Marie Magdelaine Coudé, Nicola Gokbuget, et al.
Haematologica|March 9, 2023
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 studyCorentin Orvain, Sylvain Chantepie, Xavier Thomas, et al.
NEJM Evidence|June 24, 2025
Intermediate-Dose Cytarabine as Postinduction AML TherapyMathilde Hunault, Cécile Pautas, Sarah Bertoli, et al.
European Journal of Haematology|March 25, 2021
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trialAnne Bouvier, Jean-François Hamel, Jacques Delaunay, et al.
Cytotherapy|November 11, 2025
Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in EuropeDelphine Ammar, Carmen Sanges, David Henderson, et al.
Blood|May 21, 2026
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapyNicolas Duployez, Romane Joudinaud, Augustin Boudry, et al.
Pageof 17

Showing results (161-170 of 169) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 169 results.
Leukemia|September 18, 2020
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO studyLaetitia Largeaud, Pascale Cornillet-Lefebvre, Jean-François Hamel, et al.
Nature Communications|January 24, 2015
Site- and allele-specific polycomb dysregulation in T-cell leukaemiaJean-Marc Navarro, Aurore Touzart, Lydie C Pradel, et al.
Blood|May 13, 2026
Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST StudyNicolas Boissel, Françoise Huguet, Thibaut Tl Leguay, et al.
Blood|April 29, 2016
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALLPhilippe Rousselot, Marie Magdelaine Coudé, Nicola Gokbuget, et al.
Haematologica|March 9, 2023
Impact of central nervous system involvement in adult patients with Philadelphia-negative acute lymphoblastic leukemia: a GRAALL-2005 studyCorentin Orvain, Sylvain Chantepie, Xavier Thomas, et al.
NEJM Evidence|June 24, 2025
Intermediate-Dose Cytarabine as Postinduction AML TherapyMathilde Hunault, Cécile Pautas, Sarah Bertoli, et al.
European Journal of Haematology|March 25, 2021
Molecular classification and prognosis in younger adults with acute myeloid leukemia and intermediate-risk cytogenetics treated or not by gemtuzumab ozogamycin: Final results of the GOELAMS/FILO acute myeloid leukemia 2006-intermediate-risk trialAnne Bouvier, Jean-François Hamel, Jacques Delaunay, et al.
Cytotherapy|November 11, 2025
Call for preserving specialized knowledge and contributions of the CAT to advancing ATMPs in EuropeDelphine Ammar, Carmen Sanges, David Henderson, et al.
Blood|May 21, 2026
Prognostic impact of FLT3-ITD microclones in young adults with acute myeloid leukemia treated with intensive chemotherapyNicolas Duployez, Romane Joudinaud, Augustin Boudry, et al.
Pageof 17